Neuren Pharmaceuticals Ltd. Registered Shares o.N.
- BID
10.3
- ASK
10.8
- 100 Units100 Units
- 07/22, 18:36:31 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
21.21%
Market Cap
-
P/E Ratio
78.42
Dividend Yield
0.00 %
Earnings per Share
0.14 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 10.3 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 06:31:38 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 10.4 | 10.3 |
| PREV. DAY'S PRICE | 10 | (07/21) |
| CHANGE DAY BEFORE | +0.30 | 3.00 % |
| 52 WEEK HIGH / LOW | 12.1 (10/30) | 6.4 (03/30) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.76 | 0.68 | 0.14 | 0.17 | 0.27 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 20.20 | 11.24 | 78.42 | 60.86 | 38.09 |
PRICE - BOOK RATIO | 15.49 | 4.36 | 6.96 | - | - |
PRICE - SALES RATIO | 14.08 | 7.67 | 37.65 | - | - |
PRICE - CASH FLOW RATIO | 17.66 | - | 19.40 | - | - |
Master Data
| WKN | A0DPHQ |
| ISIN | NZNEUE0001S8 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | NEUREN PHARMACEUTICALS |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.50 % | 32.45 % | 36.05 % | 0.00 % | 21.21 % | - | - | -4.76 % |
| HIGH | 10.50 | 10.50 | 10.50 | 10.50 | 12.10 | - | - | 12.00 |
| LOW | 10.00 | 7.15 | 7.05 | 6.40 | 6.40 | - | - | 6.40 |
Dividende
pro Aktie
NEUREN PHARMACEUTICALS does not deliver dividend information
Company profile
Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the Commercial Products, and Research and Development segments. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.